Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 4: Differenzialdiagnosen, Stadieneinteilung, Remission

Autor/en: Hartmut Goldschmidt
Letzte Änderung: 30.06.2011
  • Avet-Loiseau H et al.
    Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome.
    Blood 2007;109:3489-3495. PMID:17209057
    [Medline]


  • Bladé J, Kyle RA.
    Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.
    Hematol Oncol Clin North Am 1999;13:1259-1272. PMID:10626149
    [Medline]


  • Bladé J et al.
    Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
    Br J Haematol 1998;102:1115-1123. PMID:9753033
    [Medline]


  • Bladé J et al.
    Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommandations.
    J Clin Oncol 2010;28:690-697. PMID:20026810
    [Medline]


  • Chamberlain MC, Glantz M.
    Myelomatous meningitis.
    Cancer 2008;112:1562-1567. PMID:18260094
    [Medline]


  • Chee CE et al.
    The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma.
    Blood 2009;114:2617-2618. PMID:19641191
    [Medline]


  • Costello R et al.
    Primary plasma cell leukaemia: a report of 18 cases.
    Leuk Res 2001;25:103-107. PMID:11166824
    [Medline]


  • Dimopoulos M et al.
    Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
    Blood 2000;96:2037-2044. PMID:10979944
    [Medline]


  • Dispenzieri A et al.
    Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
    Blood 2008a;111:785-789. PMID: 17942755
    [Medline]


  • Dispenzieri A.
    POEMS syndrome.
    Blood Rev 2007;21:285-299. PMID:17850941
    [Medline]


  • Dispenzieri A et al.
    Appraisal of immunoglobulin free light chain as a marker of response.
    Blood 2008b;111:4908-4915. PMID:18364469
    [Medline]


  • Drayson M et al.
    Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.
    Blood 2001;97:2900-2902. PMID:11313287
    [Medline]


  • Durie BG et al.
    Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
    Hematol J 2003;4:379-398. PMID:14671610
    [Medline]


  • Durie BG et al.
    International uniform response criteria for multiple myeloma.
    Leukemia 2006;20:1467-1473. PMID:16855634
    [Medline]


  • Durie BG, Salmon SE.
    A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
    Cancer 1975;36:842-854. PMID:1182674
    [Medline]


  • Greipp PR et al.
    International staging system for multiple myeloma.
    J Clin Oncol 2005;23:3412-3420. PMID:15809451
    [Medline]


  • Hari PN et al.
    Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
    Leukemia 2009;23:1528-1534. PMID:19322205
    [Medline]


  • Harousseau JL, Attal M, Avet-Loiseau H.
    The role of complete response in multiple myeloma.
    Blood 2009;114:3139-3146. PMID:19638622
    [Medline]


  • Hillengass J et al.
    Prognostic significance of focal lesions in whole body magnetic resonance imaging in patients with asymptomatic multiple myeloma.
    J Clin Oncol 2010;28:1606-1610. PMID:20177023
    [Medline]


  • International Myeloma Working Group.
    Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
    Br J Haematol 2003;121:749-757. PMID:12780789
    [Medline]


  • Kariyawasan CC et al.
    Multiple myeloma: causes and consequences of delay in diagnosis.
    QJM 2007;100:635-640. PMID:17846059
    [Medline]


  • Kröger N et al.
    Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
    Exp Hematol 2009;37:791-798. PMID:19487069
    [Medline]


  • Kumar S et al.
    Bone marrow angiogenesis in multiple myeloma: effect of therapy.
    Br J Haematol 2002;119:665-671. PMID:12437642
    [Medline]


  • Kyle RA, Greipp PR.
    Smoldering multiple myeloma.
    N Engl J Med 1980;302:1347-1349. PMID:7374679
    [Medline]


  • Kyle RA et al.
    Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.
    Blood 2003a;102:3759-3764. PMID:12881316
    [Medline]


  • Kyle RA et al.
    Review of 1027 patients with newly diagnosed multiple myeloma.
    Mayo Clin Proc 2003b;78:21-33. PMID:12528874
    [Medline]


  • Kyle RA et al.
    Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
    N Engl J Med 2007;356:2582-2890. PMID:17582068
    [Medline]


  • Landgren O et al.
    Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.
    Blood 2009;113:5412-5417. PMID:19179464
    [Medline]


  • Mahtouk K et al.
    Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.
    Clin Cancer Res 2007;13:7289-7295. PMID:18094409
    [Medline]


  • Matsui S et al.
    Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma.
    Stat Med 2008;27:1106-1120. PMID:17680552
    [Medline]


  • mSMART.
    Stratification for Myeloma And Risk-adapted Therapy.
    http://www.msmart.org


  • Neben K et al.
    Combining chromosomal aberrations t(4;14) and del(17p13) with ISS allows a stratification of myeloma patients undergoing autologous stem cell transplantation.
    Haematologica 2010;95:1150-1157. PMID:20220069
    [Medline]


  • Pérez-Persona E et al.
    New criteria to identify risk of progression in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
    Blood 2007;110:2586-2592. PMID:17576818
    [Medline]


  • Shaw GR.
    Nonsecretory plasma cell myeloma - becoming even more rare with serum free light chain assay.
    Arch Pathol Lab Med 2006;130:1212-1215. PMID:16879026
    [Medline]


  • Snozek Cl et al.
    Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.
    Leukemia 2008;22:1933-1937. PMID:18596742
    [Medline]


  • Vacca A, Ribatti D.
    Bone marrow angiogenesis in multiple myeloma.
    Leukemia 2006;20:193-199. PMID:16357836
    [Medline]


  • Varettoni M et al.
    Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients.
    Ann Oncol 2010;21:325-330. PMID:19633044
    [Medline]


  • Waldenström J.
    Incipient myelomatosis or „essential“ hyperglobulinemia with fibrinogenopenia: a new syndrome?
    Acta Medica Scandinavica 1944;216:433-434.


  • Walker R et al.
    Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
    J Clin Oncol 2007;25:1121-1128. PMID:17296972
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]